Hypoxia, clonal selection, and the role of HIF-1 in tumor progression

被引:554
作者
Semenza, GL
机构
[1] Johns Hopkins Univ Hosp, Sch Med, Inst Med Genet, Dept Med, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Sch Med, Inst Med Genet, Dept Pediat, Baltimore, MD 21287 USA
基金
美国国家卫生研究院;
关键词
angiogenesis; cancer; glycolysis p53; Ras; vascular endothelial growth factor;
D O I
10.1080/10409230091169186
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor progression occurs as a result of the clonal selection of cells in which somatic mutations have activated oncogenes or inactivated tumor suppressor genes leading to increased proliferation and/or survival within the hypoxic tumor microenvironment. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that mediates adaptive responses to reduced O-2 availability, including angiogenesis and glycolysis. Expression of the O-2-regulated HIF-1(alpha) subunit and HIF-1 transcriptional activity are increased dramatically in hypoxic cells. Recent studies indicate that many common tumor-specific genetic alterations also lead to increased HIF-1 alpha expression and/or activity. Thus, genetic and physiologic alterations within tumors act synergistically to increase HIF-1 transcriptional activity, which appears to play a critical role in the development of invasive and metastatic properties that define the lethal cancer phenotype.
引用
收藏
页码:71 / 103
页数:33
相关论文
共 214 条
  • [1] Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma
    Abdulrauf, SI
    Edvardsen, K
    Ho, KL
    Yang, XY
    Rock, JP
    Rosenblum, ML
    [J]. JOURNAL OF NEUROSURGERY, 1998, 88 (03) : 513 - 520
  • [2] Mersalyl is a novel inducer of vascular endothelial growth factor gene expression and hypoxia-inducible factor 1 activity
    Agani, F
    Semenza, GL
    [J]. MOLECULAR PHARMACOLOGY, 1998, 54 (05) : 749 - 754
  • [3] Agani F, 1997, CANCER RES, V57, P4474
  • [4] Stabilization of wild-type p53 by hypoxia-inducible factor 1α
    An, WG
    Kanekal, M
    Simon, MC
    Maltepe, E
    Blagosklonny, MV
    Neckers, LM
    [J]. NATURE, 1998, 392 (6674) : 405 - 408
  • [5] Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
  • [6] 2-Z
  • [7] An essential role for p300/CBP in the cellular response to hypoxia
    Arany, Z
    Huang, LE
    Eckner, R
    Bhattacharya, S
    Jiang, C
    Goldberg, MA
    Bunn, HF
    Livingston, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) : 12969 - 12973
  • [8] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
    Arap, W
    Pasqualini, R
    Ruoslahti, E
    [J]. SCIENCE, 1998, 279 (5349) : 377 - 380
  • [9] Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
    Arbiser, JL
    Moses, MA
    Fernandez, CA
    Ghiso, N
    Cao, YH
    Klauber, N
    Frank, D
    Brownlee, M
    Flynn, E
    Parangi, S
    Byers, HR
    Folkman, J
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) : 861 - 866
  • [10] Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
    Benjamin, LE
    Keshet, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) : 8761 - 8766